Medytox Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
757
- Stock Symbol
-
086900
- Investments
-
13
- Share Price
-
$83.39
- (As of Tuesday Closing)
Medytox General Information
Description
Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. The group provides its products under the brand names of Neuronox, Siax and others. It distributes its products within Korean and to overseas markets, such as Japan, China, Russia and Europe, among others.
Contact Information
Website
medytox.comCorporate Office
- Medytox Building, 626
- Teheran-ro, Gangnam-gu
- Seoul, 06175
- South Korea
Corporate Office
- Medytox Building, 626
- Teheran-ro, Gangnam-gu
- Seoul, 06175
- South Korea
Medytox Stock Performance
As of 14-Jan-2025, Medytox’s stock price is $83.39. Its current market cap is $555M with 6.66M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $83.39 | $83.02 | $81.33 - $178.63 | $555M | 6.66M | 59.8K | $1.18 |
Medytox Financials Summary
As of 30-Sep-2024, Medytox has a trailing 12-month revenue of $179M.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 1,032,766 | 1,295,489 | 698,806 | 743,870 |
| Revenue | 179,449 | 169,124 | 150,989 | 161,399 |
| EBITDA | 24,488 | 24,984 | 51,334 | 131,257 |
| Net Income | 8,697 | 7,461 | 28,643 | 82,200 |
| Total Assets | 477,003 | 474,612 | 472,154 | 485,453 |
| Total Debt | 62,144 | 64,275 | 95,702 | 111,693 |
Medytox Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Medytox Comparisons
Industry
Financing
Details
Medytox Competitors (27)
One of Medytox’s 27 competitors is Dr. Reddy's Laboratories, a Corporation company based in Hyderabad, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dr. Reddy's Laboratories | Corporation | Hyderabad, India | ||||
| GlaxoSmithKline Consumer Nigeria | Corporation | Lagos, Nigeria | ||||
| Lupin | Corporation | Mumbai, India | ||||
| Abbott India | Corporation | Mumbai, India | ||||
| Lannett Company | Corporation | Trevose, PA |
Medytox Patents
Medytox Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3238234-A1 | Botulinum neurotoxin composition | Pending | 15-Nov-2021 | ||
| EP-4434537-A1 | Botulinum neurotoxin composition | Pending | 15-Nov-2021 | ||
| US-20240294893-A1 | Recombinant botulinum toxin type a light chain, recombinant botulinum toxin, and composition, use, and method thereof | Pending | 28-Jun-2021 | ||
| EP-4365190-A1 | Recombinant botulinum toxin type a light chain, recombinant botulinum toxin, and composition, use, and method thereof | Pending | 28-Jun-2021 | ||
| EP-4365191-A1 | Recombinant botulinum toxin type a light chain, recombinant botulinum toxin, and composition, use, and method thereof | Pending | 28-Jun-2021 | C12N9/52 |
Medytox Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Medytox Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Medytox Investments & Acquisitions (13)
Medytox’s most recent deal was a Early Stage VC with Aigen Sciences for . The deal was made on 01-Oct-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Aigen Sciences | 01-Oct-2024 | Early Stage VC | Drug Delivery | ||
| Aigen Sciences | 04-Oct-2022 | Seed Round | Drug Delivery | ||
| Lysentech | 22-Dec-2021 | Early Stage VC | Drug Discovery | ||
| Evolus | 01-Sep-2021 | Secondary Transaction - Private | Pharmaceuticals | ||
| Cellapeutics Bio | 28-Jul-2021 | Seed Round | Biotechnology |
Medytox ESG
Risk Overview
Risk Rating
Updated November, 30, 2024
39.99 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,104
Rank
Percentile
Pharmaceuticals
Industry
of 851
Rank
Percentile
Biotechnology
Subindustry
of 367
Rank
Percentile
Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Medytox Venture Investment | Seoul, South Korea | 2017 |
Medytox FAQs
-
When was Medytox founded?
Medytox was founded in 2000.
-
Where is Medytox headquartered?
Medytox is headquartered in Seoul, South Korea.
-
What is the size of Medytox?
Medytox has 757 total employees.
-
What industry is Medytox in?
Medytox’s primary industry is Pharmaceuticals.
-
Is Medytox a private or public company?
Medytox is a Public company.
-
What is Medytox’s stock symbol?
The ticker symbol for Medytox is 086900.
-
What is the current stock price of Medytox?
As of 14-Jan-2025 the stock price of Medytox is $83.39.
-
What is the current market cap of Medytox?
The current market capitalization of Medytox is $555M.
-
What is Medytox’s current revenue?
The trailing twelve month revenue for Medytox is $179M.
-
Who are Medytox’s competitors?
Dr. Reddy's Laboratories, GlaxoSmithKline Consumer Nigeria, Lupin, Abbott India, and Lannett Company are some of the 27 competitors of Medytox.
-
What is Medytox’s annual earnings per share (EPS)?
Medytox’s EPS for 12 months was $1.18.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
